{"id":"W4413810210","doi":"10.1016/s2152-2650(25)01007-9","title":"POSTER: ABCL-544 Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): 2 Year Follow-Up of the Phase 3 STARGLO Trial","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Gemcitabine; Diffuse large B-cell lymphoma; Oxaliplatin; Refractory (planetary science); Internal medicine; Phases of clinical research; Lymphoma; Oncology; Chemotherapy; Cancer; Colorectal cancer; Metallurgy; Materials science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001006458,0.0007718373,0.00128668,0.000183959,0.0002716975,0.000958038,0.0004694072,0.0008625782,0.005489808],"category_scores_gemma":[0.0006842023,0.0002591036,0.001590987,0.0002188219,0.0004197161,0.000648729,0.000407576,0.002255327,0.001170799],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006355094,"about_ca_system_score_gemma":0.0006219296,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008450957,"about_ca_topic_score_gemma":0.002135641,"domain_scores_codex":[0.9997625,0.0001073715,0.00001310303,0.00003743728,0.00001833712,0.00006124084],"domain_scores_gemma":[0.9996392,0.00006544486,0.00007413767,0.00002307572,0.00001983405,0.0001783703],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7684935,0.005860666,0.007380445,0.001190909,0.003588816,0.0001987019,0.0001619359,0.002582582,0.008575452,0.0003412823,0.02546022,0.1761655],"study_design_scores_gemma":[0.6883071,0.219118,0.06092766,0.0002260898,0.003955889,0.0005960582,0.0001750969,0.002247848,0.003870473,0.0008836633,0.01960303,0.00008893129],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9743387,0.0132321,0.000358766,0.003121413,0.0009113932,0.0004763707,0.002549013,0.0001864837,0.004825723],"genre_scores_gemma":[0.9780677,0.005861791,0.0006810501,0.003360037,0.0004812404,0.0003237215,0.0042565,0.00004854273,0.006919398],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005489808,"threshold_uncertainty_score":0.0183652,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01346425070777358,"score_gpt":0.2872150006567484,"score_spread":0.2737507499489748,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}